invIOs becomes an entirely separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline
VIENNA, Austria, April 26, 2022 (GLOBE NEWSWIRE) — APEIRON Biologics SA announces that the annual general meeting held yesterday approved the new group structure by splitting off its preclinical and clinical development activities and creating a new, entirely separate holding company, invIOs Holding AG.
The approved split of the 100% stake of APEIRON Biologics AG in invIOs GmbH (invIOs) leads to the creation of invIOs Holding AG, which combines the activities of its 100% subsidiaries, invIOs GmbH and APEIRON Respiratory Therapies GmbH (AResT ). Shareholders of APEIRON Biologics AG will receive shares of invIOs Holding AG in proportion to their current stake in APEIRON Biologics AG.
invIOs will continue to focus on developing new immuno-oncology treatments for hard-to-treat cancers with its Enhancement Platform for immune Cells (EPiC) cell therapy platform and its lead clinical-stage asset, APN401. AResT will lead the development of APN01, currently in development for the treatment of COVID-19 and other respiratory and pulmonary indications.
APEIRON Biologics AG continues to own the intellectual property and license to its marketed product, Qarziba® (APN311), which is licensed worldwide to EUSA Pharma Ltd.
Peter Llewellyn-Davies, CEO of invIOs, commented: “Our highly experienced team, with core competency in immuno-oncology and a proven track record in successful drug development and bringing them to market, is already hard at work advancing our new programs in the hard-to-treat cancers with the goal of bringing important new treatment options to critically ill patients.
“The new group structure approved by the AGM is an important step forward in fostering our innovation and growth, and we are grateful to our shareholders for their continued support. We believe this new structure will facilitate invIOs’ access to funding from international life science investors and partners, allowing us to realize the full potential of our exciting immuno-oncology pipeline.
invIOs is a private biotechnology company based in Vienna, Austria, focused on the discovery and development of innovative cancer immunotherapies. The proprietary EPiC (Enhancement Platform for immune Cells) cell therapy technology platform for silencing intracellular IO targets, enables rapid treatment of patients using their own cells by employing short out-of-body times in an outpatient setting. The new concept allows access and treatment of indications that were not previously addressable by cell therapy.
APN401 is the first clinical-stage candidate based on invIOs’ EPiC cell therapy platform. The clinical program is a first-in-class outpatient autologous transient cell therapy to enhance immune reactivity via an intracellular master checkpoint inhibitor, Cbl-b. APN401 is currently being evaluated in a Phase 1b clinical trial in patients with advanced solid tumors.
The second candidate from the platform is INV441, a preclinical-stage cell therapy program aimed at activating tumor-associated immune cells.
Third, the orally-administered small molecule candidate INV501 is being developed to target tumor-specific immune activation via a different entry point.
About APEIRON Respiratory Therapies GmbH (AResT)
AResT is a 100% subsidiary of invIOs GmbH focused on the discovery and development of innovative treatments for respiratory diseases.
AResT is developing APN01 (rhsACE2, alumacedase alfa), a soluble recombinant version of the SARS-CoV-2 cell entry receptor ACE2. APN01 has shown potential clinical benefits for COVID-19 in a double-blind, placebo-controlled Phase 2 trial and has potential in other respiratory diseases such as acute respiratory distress syndrome (ARDS) and high blood pressure pulmonary (PAH). APN01 is under development for inhalation.
About APEIRON Biologics AG
APEIRON Biologics is a private biotechnology company based in Vienna, Austria. APEIRON received EU marketing authorization for APN311 (dinutuximab beta, Qarziba®) in 2017 for the treatment of pediatric patients with neuroblastoma and licensed exclusive worldwide rights for this product to EUSA Pharma ltd.
For more information, please contact:
Media and investor relations
MC Services SA
Raimund Gabriel, Laurie Doyle, Andreas Jungfer
E-mail: [email protected]
The information in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of APEIRON, invIOs and related companies as of the date of this press release. These forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. forward-looking statements. We expressly disclaim any obligation or undertaking to publicly post any updates or revisions to these statements.